Investing.com - Financial Markets Worldwide

Iterum Therapeutics PLC (ITRM)

NASDAQ
Symbol
Exchange
Currency
1.475
+0.025(+1.72%)
-Closed.
Currency in USD
After Hours
1.550
+0.075(+5.085%)
- Real-time Data
  • Volume:
    104,565
  • Day's Range:
    1.410 - 1.500
  • 52 wk Range:
    0.601 - 7.050
Unusual Post-Market activity

Post-market activity occurs after regular market hours and can be used to judge market strength and direction. Post-market trading has some risk because of lower liquidity and more volatility than regular sessions.

ITRM Overview

Prev. Close
1.45
Day's Range
1.41-1.5
Revenue
-
Open
1.45
52 wk Range
0.601-7.05
EPS
-3.55
Volume
104,565
Market Cap
17.86M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
367,151
P/E Ratio
-0.42
Beta
1.41
1-Year Change
-75.76%
Shares Outstanding
12,233,374
Next Earnings Date
Mar 27, 2023
What is your sentiment on Iterum Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Iterum Therapeutics PLC News

Iterum Therapeutics PLC Analysis

Iterum Therapeutics PLC Company Profile

Iterum Therapeutics PLC Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
13
Market
United States

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to improve the lives of people affected by serious and life-threatening diseases around the world. The Company is focused on developing and commercializing sulopenem, which is an oral and intravenous penem. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It is also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes, such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms, including methicillin-susceptible staphylococci, and others.

Read More

Income Statement

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyBuySell
Technical IndicatorsBuyBuyStrong BuyStrong BuyStrong Sell
SummaryNeutralBuyStrong BuyStrong BuyStrong Sell

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
Apple
154.50157.38147.83+3.68+2.44%153.13MNASDAQ
Meta Platforms
186.53196.77182.89-2.24-1.19%76.54MNASDAQ
Alphabet A
104.78107.81102.58-2.96-2.75%64.92MNASDAQ
Pfizer
44.0644.3943.88-0.28-0.63%23.71MNYSE
J&J
164.61166.34163.89-0.93-0.56%6.84MNYSE
Costco
514.80521.55512.50-8.63-1.65%1.83MNASDAQ
Tesla
189.98199.00183.69+1.71+0.91%230.29MNASDAQ
Microsoft
258.35264.20257.10-6.26-2.36%28.73MNASDAQ
Amazon.com
103.39108.78102.52-9.52-8.43%143.31MNASDAQ
Nio A ADR
11.1911.9011.16-0.77-6.44%55.80MNYSE
Rivian Automotive
19.9021.3219.75-0.98-4.69%27.18MNASDAQ
Coca-Cola
59.8360.4259.23-0.45-0.75%15.38MNYSE
Goldman Sachs
369.95374.57365.44+0.48+0.13%2.22MNYSE
JPMorgan
141.09142.33138.13+2.15+1.55%11.48MNYSE
McDonald’s
264.23265.22261.35+1.02+0.39%3.00MNYSE
  • any news
    0
    • ITRM today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Friday, November 12, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
      2
      • Should buy or not
        0
        • I have !
          0
        • Buy.
          0
      • Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced a data presentation at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021.Title: In Vitro Antibacterial Susceptibility Testing of Sulopenem Against Category A and B Bio-threat Bacterial Pathogens
        0
        • This study is not listed in their pipeline. But I suppose the news must be good.......
          0
      • ITRM today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTI). In July, the Company announced that it had received a Complete Response Letter (CRL) from the FDA requesting additional data to support approval of oral sulopenem for the treatment of adult women with a uUTI. “We had a successful meeting with the FDA and have established various potential paths forward to address the request in the CRL for additional data in support of our NDA,” said Corey Fishman, Chief Executive Officer. “We are currently evaluating the optimal design for an additional Phase 3 uUTI study to be conducted prior to the potential resubmission of the NDA. We continue to believe in the ability of sulopenem to treat the growing problem of multi-drug resistant UTIs in the community.”. Iterum notes that cash, cash equivalents and short-term investments were $91.5 million at the end of the second quarter of 2021. Based on the current operating plan and subject to final determination of the design and planned conduct of additional clinical and potential nonclinical development for sulopenem, the Company believes that it is well positioned financially to fund its operations into the second half of 2023.
        0
        • Iterum Therapeutics (ITRM): Q2 Non-GAAP EPS of -$0.04 beats by $0.02; GAAP EPS of $0.04 beats by $0.11.Cash, cash equivalents and short-term investments of $91.44M.Press Release“Despite...
          0
          • Good news on the way
            0
            • what good news?
              0
          • Any one can analyse here plz
            0
            • i can analyse ... how i can help you ? 🤭
              0
          • "the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Friday, August 13, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business." - Before the open, this might be a good omen.
            0
            • news source plz ?
              0
            • ITERUm investor relations page
              0
            • Patient Guythanks bro
              0
          • hold... and wait for the homerun pay day when it hits 2.50
            0